mrc

MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.

MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.

Aptuscan, a spin out company based on research carried out at the MRC Cancer Cell Unit, has been acquired by Avacta, an AIM-listed biotechnology company.

MRC Technology announced today that they have entered into an agreement with the Association for International Cancer Research (AICR) to assist in the oversight and management of intellectual property (IP) arising from AICR-funded projects.